446 related articles for article (PubMed ID: 25630663)
1. Recent developments in L-asparaginase discovery and its potential as anticancer agent.
Shrivastava A; Khan AA; Khurshid M; Kalam MA; Jain SK; Singhal PK
Crit Rev Oncol Hematol; 2016 Apr; 100():1-10. PubMed ID: 25630663
[TBL] [Abstract][Full Text] [Related]
2. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
3. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
[TBL] [Abstract][Full Text] [Related]
5. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
6. L-asparaginase: a promising chemotherapeutic agent.
Verma N; Kumar K; Kaur G; Anand S
Crit Rev Biotechnol; 2007; 27(1):45-62. PubMed ID: 17364689
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
8.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
Narta UK; Kanwar SS; Azmi W
Crit Rev Oncol Hematol; 2007 Mar; 61(3):208-21. PubMed ID: 17011787
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL.
Ali U; Naveed M; Ullah A; Ali K; Shah SA; Fahad S; Mumtaz AS
Eur J Pharmacol; 2016 Jan; 771():199-210. PubMed ID: 26698391
[TBL] [Abstract][Full Text] [Related]
13. Endophytic Fungi as a Promising Source of Anticancer L-Asparaginase: A Review.
Parashiva J; Nuthan BR; Rakshith D; Satish S
Curr Microbiol; 2023 Jul; 80(9):282. PubMed ID: 37450223
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Kang SM; Rosales JL; Meier-Stephenson V; Kim S; Lee KY; Narendran A
Oncogene; 2017 Oct; 36(42):5910-5913. PubMed ID: 28650467
[TBL] [Abstract][Full Text] [Related]
15. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
[TBL] [Abstract][Full Text] [Related]
16. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
17. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
18. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
20. L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.
Ramya LN; Doble M; Rekha VP; Pulicherla KK
Appl Biochem Biotechnol; 2012 Aug; 167(8):2144-59. PubMed ID: 22684410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]